Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients
Steinkamp G, Demmelmair H, Rühl-Bagheri I, von der Hardt H, Koletzko B
Journal of pediatric gastroenterology and nutrition · 44 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2000-10-01 · J Pediatr Gastroenterol Nutr · vol. 31 · número 4 · págs. 418–423
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 83 citas · más que el 89% de estudios similares · 2.6× el promedio de su campo
- Referencias
- 40 trabajos
- Acceso
- De pago
- Áreas de investigación
- Cystic Fibrosis Research Advances · Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health
- Palabras clave
- cystic fibrosis, linoleic acid, energy supplements, essential fatty acids, body weight, steatorrhea, arachidonic acid, plasma phospholipid fatty acids, nutrition counseling, fat mass, long-chain polyunsaturated fatty acids
- MeSH
- humans, celiac disease, cystic fibrosis, body weight, fatty acids, essential, linoleic acid, energy intake, dietary supplements, adolescent, child, female, male
5 autores
- Gratiana Steinkamp🇩🇪Medizinische Hochschule Hannover
- Hans Demmelmair🇩🇪Ludwig-Maximilians-Universität München
- Ina Rühl‐Bagheri🇩🇪Medizinische Hochschule Hannover
- Horst von der Hardt🇩🇪Medizinische Hochschule Hannover
- Berthold Viktor Koletzko🇩🇪 · autor de correspondenciaLudwig-Maximilians-Universität München
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Patients with cystic fibrosis who have steatorrhea frequently are underweight and have essential fatty acid (EFA) depletion, which is associated with a poor clinical course. It has been stated that poor EFA status is difficult to correct in patients with cystic fibrosis, and an impaired EFA metabolism with reduced synthesis of long-chain polyunsaturated fatty acids has been proposed. In this study, the effects of an oral energy supplement rich in linoleic acid were investigated in patients with cystic fibrosis who had a body weight below 95% of normal for height.
Methods
Thirty-six patients (16 girls) more than 4 years of age were randomized either to a control group (n = 20, age 13.3 +/- 3.8 years, mean +/- SD) receiving intensive dietary counseling only, or an intervention group (n = 16, age, 10.4 +/- 4.3 years) treated for 3 months with dietary counseling plus 628 +/- 254 mL (= kcal) per day of an energy supplement rich in fat (31% of energy) and linoleic acid (16% of energy).
Results
In contrast to the control group, the patients with supplemented diets achieved significant increases of energy intake (2189 +/- 731 kcal/day vs. 2733 +/- 762 kcal/day), weight for height (82.8% +/- 8.6% vs. 84.8% +/- 9.6% of normal), and body fat (5.1 +/- 1.7 kg vs. 5.8 +/- 2.2 kg) as well as the initially low values of plasma phospholipid linoleic acid (11.8% +/- 1.1% vs. 17.6% +/- 1.6% of total phospholipid fatty acids) and its main metabolite arachidonic acid (4.4% +/- 0.4% vs. 5.9% +/- 0.3%).
Conclusions
Patients with cystic fibrosis with low body weight and poor EFA status benefit from EFA-rich energy supplements and can synthesize arachidonic acid from the precursor linoleic acid.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.